Improvements of nuclease and nickase gene modification techniques for the treatment of genetic diseases.

IF 4.9 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Frontiers in genome editing Pub Date : 2022-07-26 eCollection Date: 2022-01-01 DOI:10.3389/fgeed.2022.892769
Yaoyao Lu, Cedric Happi Mbakam, Bo Song, Eli Bendavid, Jacques-P Tremblay
{"title":"Improvements of nuclease and nickase gene modification techniques for the treatment of genetic diseases.","authors":"Yaoyao Lu,&nbsp;Cedric Happi Mbakam,&nbsp;Bo Song,&nbsp;Eli Bendavid,&nbsp;Jacques-P Tremblay","doi":"10.3389/fgeed.2022.892769","DOIUrl":null,"url":null,"abstract":"<p><p>Advancements in genome editing make possible to exploit the functions of enzymes for efficient DNA modifications with tremendous potential to treat human genetic diseases. Several nuclease genome editing strategies including Meganucleases (MNs), Zinc Finger Nucleases (ZFNs), Transcription Activator-like Effector Nucleases (TALENs) and Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated proteins (CRISPR-Cas) have been developed for the correction of genetic mutations. CRISPR-Cas has further been engineered to create nickase genome editing tools including Base editors and Prime editors with much precision and efficacy. In this review, we summarized recent improvements in nuclease and nickase genome editing approaches for the treatment of genetic diseases. We also highlighted some limitations for the translation of these approaches into clinical applications.</p>","PeriodicalId":73086,"journal":{"name":"Frontiers in genome editing","volume":null,"pages":null},"PeriodicalIF":4.9000,"publicationDate":"2022-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360573/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in genome editing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fgeed.2022.892769","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

Advancements in genome editing make possible to exploit the functions of enzymes for efficient DNA modifications with tremendous potential to treat human genetic diseases. Several nuclease genome editing strategies including Meganucleases (MNs), Zinc Finger Nucleases (ZFNs), Transcription Activator-like Effector Nucleases (TALENs) and Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated proteins (CRISPR-Cas) have been developed for the correction of genetic mutations. CRISPR-Cas has further been engineered to create nickase genome editing tools including Base editors and Prime editors with much precision and efficacy. In this review, we summarized recent improvements in nuclease and nickase genome editing approaches for the treatment of genetic diseases. We also highlighted some limitations for the translation of these approaches into clinical applications.

Abstract Image

Abstract Image

核酸酶和镍酶基因修饰技术在遗传性疾病治疗中的改进。
基因组编辑的进步使得利用酶的功能进行有效的DNA修饰成为可能,这对治疗人类遗传疾病具有巨大的潜力。几种核酸酶基因组编辑策略,包括巨核酶(MNs)、锌指核酸酶(ZFNs)、转录激活物样效应核酸酶(TALENs)和聚集规则间隔短回传重复序列crispr相关蛋白(CRISPR-Cas),已被开发用于纠正基因突变。CRISPR-Cas进一步被设计用于创建包括碱基编辑器和Prime编辑器在内的镍酶基因组编辑工具,具有很高的精度和效率。在这篇综述中,我们总结了核酸酶和镍酶基因组编辑方法在治疗遗传疾病方面的最新进展。我们还强调了将这些方法转化为临床应用的一些限制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
0.00%
发文量
0
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信